A Randomized, Multicenter, Double-Masked, Vehicle -Controlled Phase 2/3 Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects with Persistent Corneal Epithelial Defects (NEXPEDE-1)
Laufzeit: 01.01.2025 - 31.12.2027
imported
Kurzfassung
A Randomized, Multicenter, Double-Masked, Vehicle -Controlled Phase 2/3 Study to Evaluate the Safety and Efficacy of NEXAGON (Lufepirsen Ophthalmic Gel) in Subjects with Persistent Corneal Epithelial Defects (NEXPEDE-1)
